These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30049919)

  • 1. [Fragility Fractures in Hemodialysis Patients. Uremic toxins-related abnormal bone metabolism.].
    Yamamoto S
    Clin Calcium; 2018; 28(8):1093-1100. PubMed ID: 30049919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of uremic toxin-indoxyl sulfate on the skeletal system.
    Liu WC; Wu CC; Lim PS; Chien SW; Hou YC; Zheng CM; Shyu JF; Lin YF; Lu KC
    Clin Chim Acta; 2018 Sep; 484():197-206. PubMed ID: 29864403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
    Liu WC; Tomino Y; Lu KC
    Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P
    Kamprom W; Tawonsawatruk T; Mas-Oodi S; Anansilp K; Rattanasompattikul M; Supokawej A
    Int J Med Sci; 2021; 18(3):744-755. PubMed ID: 33437209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved dialysis removal of protein-bound uremic toxins by salvianolic acids.
    Li J; Wang Y; Xu X; Cao W; Shen Z; Wang N; Leng J; Zou N; Shang E; Zhu Z; Guo J; Duan J
    Phytomedicine; 2019 Apr; 57():166-173. PubMed ID: 30772752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
    Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
    Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
    Deltombe O; de Loor H; Glorieux G; Dhondt A; Van Biesen W; Meijers B; Eloot S
    Biochimie; 2017 Aug; 139():20-26. PubMed ID: 28528271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis.
    Takkavatakarn K; Wuttiputinun T; Phannajit J; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    J Nephrol; 2021 Dec; 34(6):1805-1817. PubMed ID: 33484425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.
    Black AP; Cardozo LF; Mafra D
    Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: Production pathway, challenges and recent advances in renal PBUTs clearance.
    Daneshamouz S; Eduok U; Abdelrasoul A; Shoker A
    NanoImpact; 2021 Jan; 21():100299. PubMed ID: 35559786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis.
    Wakamatsu T; Yamamoto S; Yoshida S; Narita I
    Toxins (Basel); 2024 May; 16(6):. PubMed ID: 38922148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique.
    Brettschneider F; Tölle M; von der Giet M; Passlick-Deetjen J; Steppan S; Peter M; Jankowski V; Krause A; Kühne S; Zidek W; Jankowski J
    Artif Organs; 2013 Apr; 37(4):409-16. PubMed ID: 23330821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating
    Chang JF; Hsieh CY; Liou JC; Lu KC; Zheng CM; Wu MS; Chang SW; Wang TM; Wu CC
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.
    Massy Z; Drueke T
    J Nephrol; 2017 Oct; 30(5):629-634. PubMed ID: 28405928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The specific impact of uremic toxins upon cognitive domains: a review.
    Franco ÁO; Starosta RT; Roriz-Cruz M
    J Bras Nefrol; 2019; 41(1):103-111. PubMed ID: 30095142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
    Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
    Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations among total p-cresylsulfate, indoxyl sulfate and hippuric acid levels with hemodialysis quality indicators in maintenance hemodialysis patients.
    Lu YC; Wu CC; Tsai IT; Hung WC; Lee TL; Hsuan CF; Yu TH; Wei CT; Chung FM; Lee YJ; Wang CP
    Clin Chim Acta; 2021 May; 516():83-91. PubMed ID: 33508250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of uremic toxins in advanced chronic kidney disease patients on maintenance hemodialysis by LC-ESI-MS/MS.
    Ragi N; Pallerla P; Babi Reddy Gari AR; Lingampelly SS; Ketavarapu V; Addipilli R; Chirra N; Kantevari S; Yadla M; Sripadi P
    Metabolomics; 2023 Feb; 19(3):14. PubMed ID: 36826619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.